Comparative Study of Adalimumab, Infliximab and Certolizumab Pegol in the Treatment of Cystoid Macular Edema Due to Behçet’s Disease

<b>Background:</b> The leading cause of blindness due to non-infectious uveitis is cystoid macular edema (CME). Behçet's disease (BD) is one of the most commonly conditions related to CME. <b>Objectives:</b> To compare the effectiveness and safety of adalimumab (ADA), infliximab (IFX) and certolizumab (CZP) in refractory CME due to BD. <b>Methods</b>: Multicenter study of BD-CME patients with no response to glucocorticoids (GCs) and at least one conventional immunosuppressive drug. At baseline, all patients presented CME, defined by OCT > 300 µ. The effectiveness of ADA, IFX and CZP was assessed over a 2-year period from baseline using the following ocular parameters: macular thickness (µm), visual acuity (BCVA), anterior chamber (AC) cells and vitritis. Mixed-effects regression models were applied. <b>Results:</b> a total of 50 patients (75 eyes) were studied (ADA = 25; IFX = 15 and CZP = 10). No significant differences in demographic parameters were found among the three groups. However, individuals in the CZP group had a significantly extended time from diagnosis to treatment onset (72 (36-120) months, <i>p</i> = 0.03) and had received a higher number of biological therapies (1.7 ± 1.1) compared to the ADA and IFX groups. Within the CZP group, ADA and IFX were previously administrated in seven patients. After 2 years of follow-up, a rapid and sustained reduction in macular thickness was noted in all three groups with no significant differences between them. Additionally, enhancements in BCVA, AC cells and vitritis were also observed. No serious adverse events were reported in the CZP group, although one isolated case of bacteremia was documented in the ADA group. ADA, IFX and CZP appear to be effective and safe treatments for refractory CME in BD. CZP seems to remain effective even in patients with an insufficient response to ADA and/or IFX. <b>Conclusions:</b> ADA, IFX and CZP appear to be effective and safe treatments for refractory CME in BD. CZP seems to remain effective even in patients with an insufficient response to ADA and/or IFX.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Medicine
Published
2024-12-04
DOI
https://doi.org/10.3390/jcm13237388
Citations
4
Primary Topic
Ocular Diseases and Behçet’s Syndrome
Type
article
Field-Weighted Citation Impact
2.15

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comparative Study of Adalimumab, Infliximab and Certolizumab Pegol in the Treatment of Cystoid Macular Edema Due to Behçet’s Disease

Patricia Moya, Miguel Cordero‐Coma, Iván Ferraz‐Amaro, Lara Sánchez-Bilbao et al.
4 citations
Journal of Clinical Medicine
Ocular Diseases and Behçet’s Syndrome
2.15
article

Comparative Study of Adalimumab, Infliximab and Certolizumab Pegol in the Treatment of Cystoid Macular Edema Due to Behçet’s Disease

Patricia Moya, Miguel Cordero‐Coma, Iván Ferraz‐Amaro, Lara Sánchez-Bilbao, Vanesa Calvo-Río, Nuria Barroso-García, Inés Hernanz-Rodríguez, Lucía Martínez‐Costa, O. Maíz, P. Fanlo, Eva Peña Saínz-Pardo, José L. Hernández, J. L. Martín-Varillas, Ángel García‐Aparicio, S. Insúa, Sergio Rodríguez-Montero, Antonio Atanes‐Sandoval, Vega Jovaní, José M. Herreras, I. Torre-Salaberri, E. Beltrán, J. R. De Dios Jiménez de Aberásturi, David Díaz‐Valle, Rosalía Demetrio‐Pablo, M. Díaz-Llopis, Ricardo Blanco, Alfredo Adán, Raquel Almodóvar-González, A. Martín-Gutiérrez, Marisa Hernández‐Garfella
article en
4 citations

Abstract

<b>Background:</b> The leading cause of blindness due to non-infectious uveitis is cystoid macular edema (CME). Behçet's disease (BD) is one of the most commonly conditions related to CME. <b>Objectives:</b> To compare the effectiveness and safety of adalimumab (ADA), infliximab (IFX) and certolizumab (CZP) in refractory CME due to BD. <b>Methods</b>: Multicenter study of BD-CME patients with no response to glucocorticoids (GCs) and at least one conventional immunosuppressive drug. At baseline, all patients presented CME, defined by OCT > 300 µ. The effectiveness of ADA, IFX and CZP was assessed over a 2-year period from baseline using the following ocular parameters: macular thickness (µm), visual acuity (BCVA), anterior chamber (AC) cells and vitritis. Mixed-effects regression models were applied. <b>Results:</b> a total of 50 patients (75 eyes) were studied (ADA = 25; IFX = 15 and CZP = 10). No significant differences in demographic parameters were found among the three groups. However, individuals in the CZP group had a significantly extended time from diagnosis to treatment onset (72 (36-120) months, <i>p</i> = 0.03) and had received a higher number of biological therapies (1.7 ± 1.1) compared to the ADA and IFX groups. Within the CZP group, ADA and IFX were previously administrated in seven patients. After 2 years of follow-up, a rapid and sustained reduction in macular thickness was noted in all three groups with no significant differences between them. Additionally, enhancements in BCVA, AC cells and vitritis were also observed. No serious adverse events were reported in the CZP group, although one isolated case of bacteremia was documented in the ADA group. ADA, IFX and CZP appear to be effective and safe treatments for refractory CME in BD. CZP seems to remain effective even in patients with an insufficient response to ADA and/or IFX. <b>Conclusions:</b> ADA, IFX and CZP appear to be effective and safe treatments for refractory CME in BD. CZP seems to remain effective even in patients with an insufficient response to ADA and/or IFX.

Journal of Clinical MedicineVol. 13(23)
Hospital Universitario de Canarias (ES), Hospital Universitario La Paz (ES), Hospital de Sant Pau (ES), Hospital Clínico San Carlos (ES), Hospital Universitari i Politècnic La Fe (ES), Hospital de Basurto (ES), Complejo Hospitalario Universitario de Santiago (ES), Complejo Hospitalario de Navarra (ES), Biogipuzkoa Health Research Institute (ES), Hospital Universitario Fundación Alcorcón (ES), Hospital Regional Universitario de Málaga (ES), Hospital Universitario Araba (ES), Instituto de Investigación Marqués de Valdecilla (ES), Hospital Clínic de Barcelona (ES), HM Hospitales (ES), Hospital Universitario Doctor Peset (ES), Hospital General Universitario De Valencia (ES), Hospital Del Mar (ES), Hospital General Universitario de Alicante Doctor Balmis (ES), Complexo Hospitalario Universitario A Coruña (ES), Hospital Universitario de Valme (ES), Hospital Universitario de Móstoles (ES), Hospital Clínico Universitario de Valladolid (ES), Universidad de Málaga (ES)
Amgen, Eli Lilly and Company, Pfizer, Sanofi, Celgene, Swedish Orphan Biovitrum, Instituto de Investigación Marqués de Valdecilla, Allergan, UCB Pharma
Good health and well-being
Openalex Percentile: Top 12%
Ocular Diseases and Behçet’s Syndrome
2.15
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.